Another phase II study with KRAS-mutant NSCLC (n = 54, including 19 with G12C, 9 with G12D, 9 with G12A) documented a trend toward worse PFS (HR = 1.86, p = 0.06) and survival (HR = 1.80, p = 0.14) in G12C patients compared to non-G12C patients (50). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.